How India Exports Amphotericin to the World

In the United States, amphotericin B is approved for various systemic fungal infections. The FDA's Orange Book lists multiple approved Abbreviated New Drug Applications (ANDAs) for amphotericin B, indicating a competitive generic market. As of March 2026, there are no active FDA import alerts specifically targeting amphotericin B from Indian manufacturers. This absence suggests compliance with FDA standards among Indian exporters. However, the presence of 180 active Indian exporters underscores the importance of maintaining stringent quality controls to ensure continued market access.

In the European Union and the United Kingdom, amphotericin B is subject to rigorous regulatory oversight. The European Medicines Agency (EMA) has granted marketing authorizations for amphotericin B formulations, contingent upon adherence to Good Manufacturing Practice (GMP) standards. Notably, in August 2006, the EMA granted orphan designation to amphotericin B for inhalation use for the prevention of pulmonary fungal infections in at-risk patients. However, this designation was later withdrawn. The UK's Medicines and Healthcare products Regulatory Agency (MHRA) aligns with EMA standards, ensuring that imported pharmaceuticals meet stringent quality and safety requirements.

Amphotericin B is included in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its critical role in treating severe fungal infections. The 24th edition of the list, published in September 2025, continues to feature amphotericin B. Additionally, the WHO Prequalification Programme has prequalified amphotericin B products, such as the 50 mg powder for dispersion for infusion manufactured by Gilead Sciences Ireland UC, as of June 2018. This prequalification facilitates procurement by UN agencies and other organizations, ensuring access to quality-assured medicines. Amphotericin B is also recognized in major pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), reflecting its established standards of quality and efficacy.

In India, amphotericin B is classified as a Schedule H drug under the Drugs and Cosmetics Act, requiring a prescription for dispensing. The National Pharmaceutical Pricing Authority (NPPA) has set ceiling prices for various formulations of amphotericin B to ensure affordability. For instance, in July 2025, the NPPA revised the ceiling price for liposomal amphotericin B injection 50 mg to ₹3,000 per vial. Export of amphotericin B necessitates a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT), ensuring compliance with national regulations and monitoring of drug exports.

The primary patents for amphotericin B have expired, leading to a robust generic market with multiple manufacturers producing the drug. This competitive landscape has contributed to the widespread availability and affordability of amphotericin B globally.

In January 2026, the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending an extension of the indication for Noxafil (posaconazole) gastro-resistant tablets to include treatment of invasive aspergillosis in adults and pediatric patients from 2 years of age weighing more than 40 kg. This development reflects the evolving therapeutic landscape for antifungal treatments.

In March 2026, the FDA issued Import Alert 16-124, focusing on aquaculture seafood products due to unapproved drugs. While not directly related to amphotericin B, this alert underscores the FDA's vigilance in monitoring imports for compliance with U.S. regulations.

In February 2026, the WHO published the 24th edition of the Model List of Essential Medicines, reaffirming the inclusion of amphotericin B as a critical antifungal agent. This inclusion highlights the ongoing global recognition of amphotericin B's importance in treating severe fungal infections.

In July 2025, the NPPA revised the ceiling price for liposomal amphotericin B injection 50 mg to ₹3,000 per vial, aiming to enhance affordability and accessibility of this essential medication in India.

In June 2025, the WHO Prequalification Programme prequalified an amphotericin B product manufactured by Gilead Sciences Ireland UC, facilitating its procurement by UN agencies and ensuring access to quality-assured medicines.

These developments reflect the dynamic regulatory and market environment surrounding amphotericin B, emphasizing the need for continuous monitoring and compliance to maintain market access and meet global health needs.

Amphotericin, a critical antifungal medication, relies on Active Pharmaceutical Ingredients (APIs) that are predominantly manufactured in India. However, the production of these APIs often depends on Key Starting Materials (KSMs) sourced from China. This dependency exposes the supply chain to potential disruptions stemming from geopolitical tensions, trade restrictions, or production issues within China.

In response to such vulnerabilities, the Indian government has implemented the Production Linked Incentive (PLI) Scheme for Bulk Drugs, initiated in July 2020. This scheme aims to bolster domestic manufacturing of critical KSMs, Drug Intermediates (DIs), and APIs, thereby reducing reliance on imports. As of September 2025, the scheme has led to the establishment of production capacities for 26 KSMs/DIs/APIs, resulting in cumulative sales of ₹2,315 crore and avoiding imports worth ₹1,807 crore.

The export market for Amphotericin from India is highly concentrated, with the top five exporters accounting for 90.8% of total exports. Notably, BHARAT SERUMS AND VACCINES LIMITED leads with a 36.8% share, followed by SUN PHARMACEUTICAL INDUSTRIES LIMITED (26.6%) and EMCURE PHARMACEUTICALS LIMITED (23.5%). This high concentration poses a significant single-source risk, as any operational or financial issues within these key companies could disrupt the supply chain.

To mitigate such risks, the PLI Scheme for Pharmaceuticals, launched in March 2021, encourages diversification and expansion of manufacturing capabilities. The scheme has attracted substantial investments, with ₹40,890 crore invested by September 2025, surpassing the initial commitment of ₹17,275 crore. This initiative aims to enhance the resilience of the pharmaceutical supply chain by promoting the production of high-value medicines and reducing dependency on a limited number of suppliers.

The global pharmaceutical supply chain is susceptible to geopolitical tensions and shipping disruptions. Critical maritime routes such as the Red Sea and the Strait of Hormuz are vulnerable to conflicts and blockades, which can delay shipments of essential raw materials and finished products. Additionally, ongoing US-China trade tensions have led to tariffs and export restrictions, further complicating the procurement of necessary components for drug manufacturing.

Regulatory bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have periodically issued shortage alerts for essential medications, including antifungal agents, due to these disruptions. Such shortages underscore the importance of a robust and diversified supply chain to ensure uninterrupted access to critical medicines like Amphotericin.

• Diversify Supplier Base: Encourage the development and support of additional manufacturers to reduce dependency on a limited number of suppliers.

• Enhance Domestic Production: Continue to invest in domestic manufacturing capabilities for APIs and KSMs to decrease reliance on imports, particularly from geopolitically sensitive regions.

• Strengthen Regulatory Compliance: Ensure that all suppliers adhere to stringent quality standards to prevent regulatory actions that could disrupt supply chains.

• Develop Contingency Plans: Establish comprehensive risk management strategies, including alternative sourcing options and inventory buffers, to mitigate potential disruptions.

• Monitor Geopolitical Developments: Stay informed about international trade policies and geopolitical events that could impact the supply chain, allowing for proactive adjustments.

RISK_LEVEL: MEDIUM